Biotechnology and precision medicine company Caris Life Sciences announced it raised $168 million in growth capital funding.. Caris Life Sciences has now raised $1.86 billion in capital since 2018.

Caris Life Sciences (CAI) priced 23.53M shares at $21.00. The deal priced above the $19.00-$20.00 range. BofA, JPMorgan and Goldman Sachs acted as joint book running managers for the offering.

Caris Life Sciences announced plans to go public, testing a technology initial public offering market that’s been frozen over for most of the year.. The Irving-based AI diagnostic company said ...

For most medtech startups, the dream of raising a billion dollars is nothing but a castle in the air. | The new funding values Caris at more than $7.8 billion and brings its total external funding ...